Increased macrophage activation inhibited by tacrolimus in the kidney of diabetic rats

Nephron - Experimental Nephrology

Volumn 128, Issue 1-2, 2014, Pages 46-56

  Wu, Yonggui ^a   Wang, Yan ^a   Qi, Xiangming ^a   Zhang, Pei ^a   Zhang, Chaoqun ^a   Zhang, Wei ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

Diabetic nephropathy; Inducible nitric oxide synthase; Macrophage; Tacrolimus; Toll like receptor

Indexed keywords

ALBUMIN; CALCINEURIN; GLUCOSE; HEMOGLOBIN A1C; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; STREPTOZOCIN; SYNAPTOTAGMIN I; TACROLIMUS; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; CALCINEURIN INHIBITOR; TLR2 PROTEIN, RAT; TLR4 PROTEIN, RAT;

ALBUMIN BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CELL ACTIVATION; CELL INFILTRATION; CELL PROLIFERATION; CONTROLLED STUDY; GLUCOSE BLOOD LEVEL; KIDNEY; KIDNEY MASS; MACROPHAGE ACTIVATION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; WESTERN BLOTTING; ANIMAL; CHEMICALLY INDUCED; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; GLOMERULUS FILTRATION RATE; MACROPHAGE; METABOLISM; PATHOLOGY; WISTAR RAT;

ANIMALS; CALCINEURIN INHIBITORS; CELL PROLIFERATION; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GLOMERULAR FILTRATION RATE; MACROPHAGE ACTIVATION; MACROPHAGES; MALE; RATS; RATS, WISTAR; STREPTOZOCIN; TACROLIMUS; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 4;

EID: 84927788600     PISSN: None     EISSN: 16602129     Source Type: Journal    
DOI: 10.1159/000366446     Document Type: Article

References (28)

1. Tuttle KR. Linking metabolism and immunology diabetic nephropathy is an inflammatory disease. J Am Soc Nephrol. 2005; 16: 1537-1538.
2. Wu YG, Ren KJ, Liang C, et al. Renoprotective effect of total glucosides of paeony (TGP) and its mechanism in experimental diabetes. J Pharmacol Sci. 2009; 109: 78-87.
3. Galkina E, Ley K. Leukocyte recruitment and vascular injury in diabetic nephropathy. J Am Soc Nephrol. 2006; 17: 368-377.
4. Tesch GH. Macrophages and diabetic nephropathy. Semin Nephrol. 2010; 30: 290-301.
5. Sassy-Prigent C, Heudes D, Mandet C, et al. Early glomerular macrophage recruitment in streptozotocin-induced diabetic rats. Diabetes. 2000; 49: 466-475.
6. Uematsu S, Akira S. Toll-like receptors and innate immunity. J Mol Med. 2006; 84: 712-725.
7. Beutler B. Inferences, questions and possibilities in Toll-like receptor signaling. Nature. 2004; 430: 257-263.
8. Mohammad MK, Morran M, Slotterbeck B, et al. Dysregulated Toll-like receptor expression and signaling in bone marrow-derived macrophages at the onset of diabetes in the nonobese diabetic mouse. Int Immunol. 2006; 18 1101-1113.
9. Devaraj S, Dasu MR, Rockwood J, et al. Increased toll-like receptor (TLR)2 and TLR4 expression in monocytes from patients with type 1 diabetes: further evidence of a proinflammatory state. J Clin Endocrinol Metab. 2008; 93: 578-583.
10. Turgut F, Bolton WK. Potential new therapeutic agents for diabetic kidney disease. Am J Kidney Dis. 2010; 55: 928-940.
11. Gooch JL, Gorin Y, Zhang BX, et al. Involvement of calcineurin in transforming growth factor-β-mediated regulation of extracellular matrix accumulation. J Biol Chem. 2000; 279 15561-15570.
12. Qi XM, Wu YG, Liang C, et al. FK506 ameliorates renal injury in early experimental diabetic rats induced by streptozotocin. Int Immunopharmacol. 2011; 11: 1613-1619.
13. Ikezumi Y, Kanno K, Koike H, et al. FK506 ameliorates proteinuria and glomerular lesions induced by anti-Thy-1.1 monoclonal antibody 1-22-3. Kidney Int. 2002; 61: 1339-1350.
14. Lan HY, Nikolic-Paterson DJ, Atkins RC. Local macrophage proliferation in experimental Goodpasture's syndrome. Nephrology. 1995; 1: 151-156.
15. Chow FY, Nikolic-Paterson DJ, Ozols E, et al. Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-Treated mice. Kidney Int. 2006; 69: 73-80.
16. Maziere C, Conte LA, Maziere JC. Activation of JAK2 by the oxidative stress generated with oxidized low-density lipoprotein. Free Radic Biol Med. 2001; 31: 1334-1340.
17. Okada S, Shikata K, Matsuda M, et al. Intercellular adhesion molecule-1-deficient mice are resistant against renal injury after induction of diabetes. Diabetes. 2003; 52: 2586-2593.
18. Wu YG, Dong J, Yuan L, et al. Nephrin and podocin loss is prevented by mycophenolate mofetil in early experimental diabetic nephropathy. Cytokine. 2008; 44: 85-91.
19. Utimura R, Fujihara CK, Mattar AL, et al. Mycophenolate mofetil prevents the development of glomerular injury in experimental diabetes. Kidney Int. 2003; 63: 209-216.
20. Yozai K, Shikata K, Sasaki M, et al. Methotrexate prevents renal injury in experimental diabetic rats via anti-inflammatory actions. J Am Soc Nephrol. 2005; 16: 3326-3338.
21. Kikuchi Y, Imakiire T, Yamada M, et al. Mizoribine reduces renal injury and macrophage infiltration in non-insulin-dependent diabetic rats. Nephrol Dial Transplant. 2005; 20: 1573-1581.
22. Tone A, Shikata K, Sasaki M, et al. Erythromycin ameliorates renal injury via anti-inflammatory effects in experimental diabetic rats. Diabetologia. 2005; 8: 2402-2411.
23. Lloberas N, Cruzado JM, Franquesa M, et al. Mammalian target of rapamycin pathway blockade slows progression of diabetic kidney disease in rats. J Am Soc Nephrol. 2006; 17 1395-1404.
24. Chow F, Ozols E, Nikolic-Paterson DJ, et al Macrophages in mouse type 2 diabetic nephropathy correlation with diabetic state and progression renal injury. Kidney Int. 2004; 65 116-128.
25. Anders HJ, Schlondorff D. Toll-like receptors emerging concepts in kidney disease. Curr Opin Nephrol Hypertens. 2007; 16: 177-183.
26. El-Achkar TM, Dagher PC. Renal Toll-like receptors: recent advances and implications for disease. Nat Clin Pract Nephrol. 2006; 2 568-581.
27. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol. 2003; 21: 335-336.
28. Dasu MR, Devaraj S, Zhao L, et al. High glucose induces Toll-like receptor expression in human monocytes mechanism of activation. Diabetes. 2008; 57: 3090-3093.